Show simple item record

RAT AND MOUSE BRAIN HISTAMINE N -METHYLTRANSFERASE: MODULATION BY METHYLATED INDOLEAMINES 1

dc.contributor.authorSellinger, Otto Z.en_US
dc.contributor.authorSchatz, Robert A.en_US
dc.contributor.authorOhlsson, W. G.en_US
dc.date.accessioned2010-04-01T15:27:01Z
dc.date.available2010-04-01T15:27:01Z
dc.date.issued1978-02en_US
dc.identifier.citationSellinger, O. Z.; Schatz, R. A.; Ohlsson, W. G. (1978). "RAT AND MOUSE BRAIN HISTAMINE N -METHYLTRANSFERASE: MODULATION BY METHYLATED INDOLEAMINES 1 ." Journal of Neurochemistry 30(2): 437-445. <http://hdl.handle.net/2027.42/65930>en_US
dc.identifier.issn0022-3042en_US
dc.identifier.issn1471-4159en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/65930
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=624949&dopt=citationen_US
dc.description.abstractA purification procedure for rat and mouse brain histamine N -methyltransferase (HMT, EC 2.1.1.8) is described which achieves the preparation of 87-fold purified rat brain and 166-fold purified mouse brain enzyme. The purified HMT (MW 29,000) is inhibited by a number of physiologically and pharmacologically active amines, among them several methylated indoleamines, at concentrations above 5 ± 10 -6 M. At concentrations below 1 ± 10 -7 M, most of the methylated indoleamines stimulate HMT , provided histamine is maintained at, or close to, its optimal concentration as an HMT substrate, namely 1 ± 10 -5 M. A study of the nature of the inhibitory process revealed a non-competitive inhibition of HMT by dopamine as against a competitive inhibition of the enzyme by most methylated indoleamines. Increasing the concentration of histamine beyond the optimal value, i.e. to inhibitory levels, resulted in less stimulation. The findings support the notion that MSO elicits the formation in selected brain cells of supranormal amounts of several methylated indoleamines which are able to stimulate HMT (and possibly other methyltransferases, see Salas et al. , 1977), thereby causing the depletion of the cerebral levels of S-adenosyl-L-methionine, reported previously (Schatz & Sellinger, 1975b).en_US
dc.format.extent678606 bytes
dc.format.extent3110 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rights1978 International Society for Neurochemistryen_US
dc.titleRAT AND MOUSE BRAIN HISTAMINE N -METHYLTRANSFERASE: MODULATION BY METHYLATED INDOLEAMINES 1en_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelNeurosciencesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumLaboratory of Neurochemistry, Mental Health Research Institute. University of Michigan Medical Center, Ann Arbor, MI 48109, U.S.A.en_US
dc.identifier.pmid624949en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/65930/1/j.1471-4159.1978.tb06548.x.pdf
dc.identifier.doi10.1111/j.1471-4159.1978.tb06548.xen_US
dc.identifier.sourceJournal of Neurochemistryen_US
dc.identifier.citedreferenceAxelrod J. & Vesell E. S. ( 1970 ) Molec. Pharmac. 6, 78 – 84.en_US
dc.identifier.citedreferenceBarth H., Lorenz W. & Niemeyer I. ( 1973 ) Hoppe-Seyler's Z. Physiol. Chem. 354, 1021 – 1026.en_US
dc.identifier.citedreferenceBrown D. D., Tomchick R. & Axelrod J. ( 1959 ) J. biol. Chem. 234, 2948 – 2950.en_US
dc.identifier.citedreferenceDeguchi T. & Barchas J. ( 1971 ) J. biol. Chem. 246, 3175 – 3181.en_US
dc.identifier.citedreferenceDiaz Borges J. M. & Urbina CH. M. ( 1976 ) Abstr. 31st Meet. Soc. Biol. Psych. p. 117.en_US
dc.identifier.citedreferenceDiez Altares M. C. & Sellinger O. Z. ( 1976 ) Enzyme 21, 53 – 65.en_US
dc.identifier.citedreferenceDuch D. S., Bowers S. W., Brenckman W. D. Jr. & Nichol C. A. ( 1976 ) Pharmacologist 18, 205.en_US
dc.identifier.citedreferenceGarbarg M., Baudry M., Benda P. & Schwartz J.-C. ( 1975 ) Brain Res. 83, 538 – 541.en_US
dc.identifier.citedreferenceGillin J. C., Kaplan J., Stillman R. & Wyatt R. J. ( 1976a ) Am. J. Psychiat. 133, 203 – 208.en_US
dc.identifier.citedreferenceGillin J. C., Tinklenberg J., Stoff D. M., Stillman R., Shortlidge J. & Wyatt R. J. ( 1976b ) Biol. Psych. 11, 355 – 358.en_US
dc.identifier.citedreferenceGustafsson A. & Forschell G. P. ( 1963 ) Acta Chem. scand. 17, 541 – 548.en_US
dc.identifier.citedreferenceHartley R. & Smith J. A. ( 1973 ) J. Pharm. Pharmac. 25, 751 – 752.en_US
dc.identifier.citedreferenceKouvelas E. D., Savakis Ch. E., Tzebelikos T., Bonatsos G. & Mitrossilis S. ( 1976 ) Experientia 32, 1136 – 1138.en_US
dc.identifier.citedreferenceLew J. Y., Matsumoto Y., Pearson J., Goldstein M., Hokfelt T. & Fuxe K. ( 1977 ) Brain Res. 119, 199 – 210.en_US
dc.identifier.citedreferenceLew J. Y., Miyamoto T. & Goldstein M. ( 1976 ) Biochem. Pharmac. 25, 1433 – 1434.en_US
dc.identifier.citedreferenceLombardini J. B., Chou T.-C. & Talalav P. ( 1973 ) Biochem. J., Lond. 135, 43 – 57.en_US
dc.identifier.citedreferenceLorenz W., Reimann H.-J., Barth J., Kusche J., Meyer R., Doenicke A. & Hutzel M. ( 1972 ) Hoppe Seyler's Z. Physiol. Chem. 353, 911 – 920.en_US
dc.identifier.citedreferenceLowry O. H., Rosebrough N. J., Farr A. L. & Randall R. J. ( 1951 ) J. biol. Chem. 193, 265 – 275.en_US
dc.identifier.citedreferenceMartres M. P., Baudry M. & Schwartz J.-C. ( 1975 ) Brain Res. 83, 261 – 275.en_US
dc.identifier.citedreferenceMerril C. R., Snyder S. H. & Bradley D. F. ( 1966 ) Biochim. biophys. Acta 118, 316 – 324.en_US
dc.identifier.citedreferenceMezei C. ( 1975 ) Brain Res. 84, 453 – 460.en_US
dc.identifier.citedreferenceOrr E. & Quay W. B. ( 1975 ) Endocrinology 96, 941 – 945.en_US
dc.identifier.citedreferenceReiner J. M. ( 1959 ) in Behavior of Enzyme Systems, p. 176. Burgess, Minneapolis MN.en_US
dc.identifier.citedreferenceRosengarten H. & Friedhoff A. J. ( 1976 ) Schizophrenia Bull. 2, 90 – 105.en_US
dc.identifier.citedreferenceSaavedra J. M., Brownstein M. J. & Palkovits M. ( 1976 ) Brain Res. 118, 152 – 156.en_US
dc.identifier.citedreferenceSaavedra J. M., Grobecker H. & Axelrod J. ( 1975 ) Science 191, 483 – 484.en_US
dc.identifier.citedreferenceSaavedra J. M., Palkovits M., Brownstein M. J. & Axelrod J. ( 1974 ) Nature 248, 695 – 696.en_US
dc.identifier.citedreferenceSalas C. E., Ohlsson W. G. & Sellinger O. Z. ( 1977 ) Biochem. Biophys. Res. Commun. 76, 1107 – 1115.en_US
dc.identifier.citedreferenceSchatz R. A., Harris R. & Sellinger O. Z. ( 1976 ) Neurochem. Res. 1, 53 – 63.en_US
dc.identifier.citedreferenceSchatz R. A. & Sellinger O. Z. ( 1975a ) J. Neurochem. 25, 73 – 78.en_US
dc.identifier.citedreferenceSchatz R. A. & Sellinger O. Z. ( 1975b ) J. Neurochem. 24, 63 – 66.en_US
dc.identifier.citedreferenceSchatz R. A. & Sellinger O. Z. ( 1977 ) Pharmacologist 19, 187.en_US
dc.identifier.citedreferenceSchatz R. A., Vunnam C. R. & Sellinger O. Z. ( 1977 ) Neurochem. Res. 2, 27 – 38.en_US
dc.identifier.citedreferenceSchayer R. W. & Reilly M. A. ( 1975 ) Agents & Actions 5, 231 – 235.en_US
dc.identifier.citedreferenceSellinger O. Z., Schatz R. A., Ashcraft E. K. & Ohlsson W. G. ( 1976 ) Trans. Am. Soc. Neurochem. 7, 237.en_US
dc.identifier.citedreferenceSnyder S. H. & Axelrod J. ( 1965 ) Biochim. biophys. Acta 111, 416 – 421.en_US
dc.identifier.citedreferenceSuriyachan D. & Thithapandha A. ( 1972 ) Biochem. biophys. Res. Commun. 48, 1199 – 1207.en_US
dc.identifier.citedreferenceTaylor K. M. ( 1973 ) Biochem. Pharmac. 22, 2775 – 2776.en_US
dc.identifier.citedreferenceTaylor K. M. & Snyder S. H. ( 1972 ) Molec. Pharmac. 8, 300 – 310.en_US
dc.identifier.citedreferenceVogel W. H., Lewis L. E. & Boehme D. M. ( 1976 ) Brain Res. 115, 357 – 359.en_US
dc.identifier.citedreferenceWhite H. L. & Wu J. C. ( 1975 ) Biochem. J., Lond. 145, 135 – 143.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.